Corrigendum to "Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms" [Heliyon Volume 10, Issue 16, August 30, 2024, Article e35847]